Multiple sclerosis update.

William T. Mayr, Moses Rodriguez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Multiple sclerosis (MS) is the most common cause of neurological disability in young European and North American adults. It is defined as dysfunction in different parts of the central nervous system at different points in time. The etiology is likely autoimmune, resulting from environmental and genetic factors. This article summarizes the symptoms, progression, diagnosis, and treatment of MS. MRI and CSF studies have been extremely helpful in identifying individual cases, but the diagnosis remains a clinical diagnosis, and one of exclusion. Methylprednisolone remains the preferred treatment for acute relapses, although plasma exchange has been shown to be helpful in cases when methylprednisolone has failed. Preventive immunomodulatory treatments are the focus of many current research efforts. Although these treatments have been shown to reduce the frequency of MS attacks, the reduction is modest, at 30%. The data that these drugs alter the progression of disability is less compelling.

Original languageEnglish (US)
Pages (from-to)36-39
Number of pages4
JournalMinnesota Medicine
Volume85
Issue number6
StatePublished - Jun 2002

Fingerprint

Multiple Sclerosis
Methylprednisolone
Plasma Exchange
Therapeutics
Central Nervous System
Recurrence
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mayr, W. T., & Rodriguez, M. (2002). Multiple sclerosis update. Minnesota Medicine, 85(6), 36-39.

Multiple sclerosis update. / Mayr, William T.; Rodriguez, Moses.

In: Minnesota Medicine, Vol. 85, No. 6, 06.2002, p. 36-39.

Research output: Contribution to journalArticle

Mayr, WT & Rodriguez, M 2002, 'Multiple sclerosis update.', Minnesota Medicine, vol. 85, no. 6, pp. 36-39.
Mayr WT, Rodriguez M. Multiple sclerosis update. Minnesota Medicine. 2002 Jun;85(6):36-39.
Mayr, William T. ; Rodriguez, Moses. / Multiple sclerosis update. In: Minnesota Medicine. 2002 ; Vol. 85, No. 6. pp. 36-39.
@article{4ac9e9edea9f40edbd606d00db86089e,
title = "Multiple sclerosis update.",
abstract = "Multiple sclerosis (MS) is the most common cause of neurological disability in young European and North American adults. It is defined as dysfunction in different parts of the central nervous system at different points in time. The etiology is likely autoimmune, resulting from environmental and genetic factors. This article summarizes the symptoms, progression, diagnosis, and treatment of MS. MRI and CSF studies have been extremely helpful in identifying individual cases, but the diagnosis remains a clinical diagnosis, and one of exclusion. Methylprednisolone remains the preferred treatment for acute relapses, although plasma exchange has been shown to be helpful in cases when methylprednisolone has failed. Preventive immunomodulatory treatments are the focus of many current research efforts. Although these treatments have been shown to reduce the frequency of MS attacks, the reduction is modest, at 30{\%}. The data that these drugs alter the progression of disability is less compelling.",
author = "Mayr, {William T.} and Moses Rodriguez",
year = "2002",
month = "6",
language = "English (US)",
volume = "85",
pages = "36--39",
journal = "Minnesota medicine.",
issn = "0026-556X",
publisher = "Minnesota Medical Association",
number = "6",

}

TY - JOUR

T1 - Multiple sclerosis update.

AU - Mayr, William T.

AU - Rodriguez, Moses

PY - 2002/6

Y1 - 2002/6

N2 - Multiple sclerosis (MS) is the most common cause of neurological disability in young European and North American adults. It is defined as dysfunction in different parts of the central nervous system at different points in time. The etiology is likely autoimmune, resulting from environmental and genetic factors. This article summarizes the symptoms, progression, diagnosis, and treatment of MS. MRI and CSF studies have been extremely helpful in identifying individual cases, but the diagnosis remains a clinical diagnosis, and one of exclusion. Methylprednisolone remains the preferred treatment for acute relapses, although plasma exchange has been shown to be helpful in cases when methylprednisolone has failed. Preventive immunomodulatory treatments are the focus of many current research efforts. Although these treatments have been shown to reduce the frequency of MS attacks, the reduction is modest, at 30%. The data that these drugs alter the progression of disability is less compelling.

AB - Multiple sclerosis (MS) is the most common cause of neurological disability in young European and North American adults. It is defined as dysfunction in different parts of the central nervous system at different points in time. The etiology is likely autoimmune, resulting from environmental and genetic factors. This article summarizes the symptoms, progression, diagnosis, and treatment of MS. MRI and CSF studies have been extremely helpful in identifying individual cases, but the diagnosis remains a clinical diagnosis, and one of exclusion. Methylprednisolone remains the preferred treatment for acute relapses, although plasma exchange has been shown to be helpful in cases when methylprednisolone has failed. Preventive immunomodulatory treatments are the focus of many current research efforts. Although these treatments have been shown to reduce the frequency of MS attacks, the reduction is modest, at 30%. The data that these drugs alter the progression of disability is less compelling.

UR - http://www.scopus.com/inward/record.url?scp=0036598008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036598008&partnerID=8YFLogxK

M3 - Article

C2 - 12092437

AN - SCOPUS:0036598008

VL - 85

SP - 36

EP - 39

JO - Minnesota medicine.

JF - Minnesota medicine.

SN - 0026-556X

IS - 6

ER -